Inhibikase Therapeutics FY23 EPS $(3.57); Cash Position $13.3M As Of Dec. 31
Portfolio Pulse from Benzinga Newsdesk
Inhibikase Therapeutics reported a FY23 EPS of $(3.57) and a cash position of $13.3M as of December 31.

March 27, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inhibikase Therapeutics reported a FY23 EPS of $(3.57) and a cash position of $13.3M as of December 31.
The reported EPS of $(3.57) indicates a loss per share for the fiscal year, which could negatively impact investor sentiment and potentially lead to a decrease in stock price in the short term. The cash position of $13.3M provides some insight into the company's liquidity, which is crucial for its operations and future investments.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100